BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 25213022)

  • 1. Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers.
    Zhang H; Liu X; Warden CD; Huang Y; Loera S; Xue L; Zhang S; Chu P; Zheng S; Yen Y
    BMC Cancer; 2014 Sep; 14():664. PubMed ID: 25213022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).
    Mazzu YZ; Armenia J; Chakraborty G; Yoshikawa Y; Coggins SA; Nandakumar S; Gerke TA; Pomerantz MM; Qiu X; Zhao H; Atiq M; Khan N; Komura K; Lee GM; Fine SW; Bell C; O'Connor E; Long HW; Freedman ML; Kim B; Kantoff PW
    Clin Cancer Res; 2019 Jul; 25(14):4480-4492. PubMed ID: 30996073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
    Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y
    Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioinformatics analysis revealing prognostic significance of
    Chen WX; Yang LG; Xu LY; Cheng L; Qian Q; Sun L; Zhu YL
    Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30898978
    [No Abstract]   [Full Text] [Related]  

  • 5. Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers.
    Ding J; Kuo ML; Su L; Xue L; Luh F; Zhang H; Wang J; Lin TG; Zhang K; Chu P; Zheng S; Liu X; Yen Y
    Carcinogenesis; 2017 May; 38(5):519-531. PubMed ID: 28379297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RRM2 expression in different molecular subtypes of breast cancer and its prognostic significance.
    Abdel-Rahman MA; Mahfouz M; Habashy HO
    Diagn Pathol; 2022 Jan; 17(1):1. PubMed ID: 34986845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma.
    Han P; Lin ZR; Xu LH; Zhong Q; Zhu XF; Liang FY; Cai Q; Huang XM; Zeng MS
    Mol Med Rep; 2015 Jul; 12(1):401-9. PubMed ID: 25695839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers.
    Liu X; Zhang H; Lai L; Wang X; Loera S; Xue L; He H; Zhang K; Hu S; Huang Y; Nelson RA; Zhou B; Zhou L; Chu P; Zhang S; Zheng S; Yen Y
    Clin Sci (Lond); 2013 May; 124(9):567-78. PubMed ID: 23113760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer.
    Shah KN; Wilson EA; Malla R; Elford HL; Faridi JS
    Mol Cancer Ther; 2015 Nov; 14(11):2411-21. PubMed ID: 26333382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance.
    Putluri N; Maity S; Kommagani R; Creighton CJ; Putluri V; Chen F; Nanda S; Bhowmik SK; Terunuma A; Dorsey T; Nardone A; Fu X; Shaw C; Sarkar TR; Schiff R; Lydon JP; O'Malley BW; Ambs S; Das GM; Michailidis G; Sreekumar A
    Neoplasia; 2014 May; 16(5):390-402. PubMed ID: 25016594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DSCAM-AS1 promotes tumor growth of breast cancer by reducing miR-204-5p and up-regulating RRM2.
    Liang WH; Li N; Yuan ZQ; Qian XL; Wang ZH
    Mol Carcinog; 2019 Apr; 58(4):461-473. PubMed ID: 30457164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and Therapeutic Significance of Adhesion-regulating Molecule 1 in Estrogen Receptor-positive Breast Cancer.
    Wu W; Zhong J; Chen J; Niu P; Ding Y; Han S; Xu J; Dai L
    Clin Breast Cancer; 2020 Apr; 20(2):131-144.e3. PubMed ID: 31669266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma.
    Jin CY; Du L; Nuerlan AH; Wang XL; Yang YW; Guo R
    Aging (Albany NY); 2020 Dec; 13(3):3518-3535. PubMed ID: 33411689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
    Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK
    Cancer; 2013 Jan; 119(2):454-62. PubMed ID: 22760605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ribonucleotide reductase subunit M2 is a potential prognostic marker and therapeutic target for soft tissue sarcoma.
    Das B; Jain N; Mallick B
    Gene; 2022 Jan; 808():145988. PubMed ID: 34624457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive bioinformatics analysis of ribonucleoside diphosphate reductase subunit M2(RRM2) gene correlates with prognosis and tumor immunotherapy in pan-cancer.
    Wu L; Yin L; Ma L; Yang J; Yang F; Sun B; Nianzeng X
    Aging (Albany NY); 2022 Oct; 14(19):7890-7905. PubMed ID: 36202136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.
    Grossi F; Dal Bello MG; Salvi S; Puzone R; Pfeffer U; Fontana V; Alama A; Rijavec E; Barletta G; Genova C; Sini C; Ratto GB; Taviani M; Truini M; Merlo DF
    Dis Markers; 2015; 2015():302649. PubMed ID: 26663950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High expression of ribonucleotide reductase subunit M2 correlates with poor prognosis of hepatocellular carcinoma.
    Lee B; Ha SY; Song DH; Lee HW; Cho SY; Park CK
    Gut Liver; 2014 Nov; 8(6):662-8. PubMed ID: 25368754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
    Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
    Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
    Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
    Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.